Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 14, 2018 - Issue 11
Submit an article Journal homepage
2,399
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Remon Abu-ElyazeedGSK, Philadelphia, PA, USACorrespondence[email protected]
View further author information
,
William JenningsRadiant Research, San Antonio, TX, USAView further author information
,
Randall SeveranceRadiant Research, Chandler, AZ, USAORCID Iconhttp://orcid.org/0000-0003-1580-5410View further author information
ORCID Icon,
Michael NossRadiant Research, Cincinnati, OH, USAView further author information
,
Adrian CaplanusiGSK, Wavre, BelgiumView further author information
,
Michael PoveyGSK, Wavre, BelgiumView further author information
&
Ouzama HenryGSK, Rockville, MD, USAView further author information
 show all
Pages 2624-2631 | Received 18 Jan 2018, Accepted 01 Jun 2018, Published online: 12 Jul 2018

References

  • World Health Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92:205−28.
  • World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301−16.
  • Centers for Disease Control and Prevention. Chapter 13: Measles. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th Edition “The Pink Book”: Centers for Disease Control and Prevention, 2015. p. 209–30.
  • Centers for Disease Control and Prevention. Chapter 15: Mumps. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th Edition “The Pink Book”: Centers for Disease Control and Prevention, 2015. p. 247–60.
  • Centers for Disease Control and Prevention. Chapter 20: Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th Edition “The Pink Book”: Centers for Disease Control and Prevention, 2012. p. 325–40.
  • Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371(9616):932−44. doi: 10.1016/s0140-6736(08)60419-5
  • World Health Organization. Mumps vaccines: WHO position paper. Wkly Epidemiol Rec. 2007;82(7):49−60.
  • McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1−34.
  • Grant GB, Reef SE, Dabbagh A, Gacic-Dobo M, Strebel PM. Global progress toward rubella and congenital rubella syndrome control and elimination – 2000–2014. MMWR Morb Mortal Wkly Rep. 2015;64(37):1052−5. doi:10.15585/mmwr.mm6437a5.
  • Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77(1):3−14.
  • Centers for Disease Control and Prevention. Measles–United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51(6):120−3.
  • Centers for Disease Control and Prevention. Mumps Cases and Outbreaks. Centers for Disease Control and Prevention; March 6, 2018 [accessed 2018 Mar13]. https://www.cdc.gov/mumps/outbreaks.html
  • Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Centers for Disease Control and Prevention; October 13, 2017 [accessed 2017 Oct 13]. https://www.cdc.gov/measles/cases-outbreaks.html
  • Hall V, Banerjee E, Kenyon C, Strain A, Griffith J, Como-Sabetti K, Heath J, Bahta L, Martin K, McMahon M, et al. Measles Outbreak – Minnesota April-May 2017. MMWR Morb Mortal Wkly Rep. 2017;66(27):713–7. doi:10.15585/mmwr.mm6627a1.
  • Gahr P, DeVries AS, Wallace G, Miller C, Kenyon C, Sweet K, Martin K, White K, Bagstad E, Hooker C, et al. An outbreak of measles in an undervaccinated community. Pediatrics. 2014;134(1):e220−8. doi:10.1542/peds.2013-4260.
  • McHale P, Keenan A, Ghebrehewet S. Reasons for measles cases not being vaccinated with MMR: investigation into parents' and carers' views following a large measles outbreak. Epidemiol Infect. 2016;144(4):870−5. doi:10.1017/S0950268815001909.
  • Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996;15(8):687−92. doi:10.1097/00006454-199608000-00010.
  • Gothefors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis. 2001;33(7):545−9. doi:10.1080/00365540110026593.
  • Gillet Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446−53. doi:10.1016/j.vaccine.2008.10.064.
  • Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003–2013. Clin Infect Dis. 2015;60(10):e58−65. doi: 10.1093/cid/civ061
  • Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin DR, Patel M, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med. 2017;377(10):947−56. doi:10.1056/NEJMoa1703309.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.